MedicaidCoverageMedium impact
KMAP BULLETIN: Preferred Drug List Update – Mid-October 2025
Kansas Medicaid (KanCare)·KS · Pharmacy, Endocrinology, Rheumatology +2 more·Pharmacy
Effective date
Oct 15, 2025
We identified it
Jun 21, 2026
Summary
KMAP (Kansas Medicaid) updated their Preferred Drug List effective October 15, 2025, moving several medications including Lopressor, ibuprofen 300mg, and denosumab products to non-preferred status while adding others like Zituvimet and Pyzchiva as preferred. Some medications like Kombiglyze XR were completely removed from the preferred drug list.
Action Required
By October 15, 2025: Pharmacy and billing teams must update prior authorization workflows for newly non-preferred medications including Lopressor (metoprolol tartrate), ibuprofen 300mg tablets, and denosumab products (Osenvelt, Xgeva, Jubbonti, Stoboclo). Update prescribing guidelines to favor newly preferred alternatives like Zituvimet, Pyzchiva, preferred NSAIDs, Tylenol, Wyost, and Prolia. Remove Kombiglyze XR from preferred formularies and ensure step therapy requirements are met for non-preferred drugs to avoid coverage denials.